Mesenchymal Stem Cells for The Treatment of Chronic Obstructive Pulmonary Disease

Exclusion Criteria

• •Subjects with history of any type of malignancy.
• •Subjects with major surgery (body organs that require anesthesia, such as tumor removal, open chest, heart surgery, abdominal surgery, intracranial surgery, or normal surgery for more than 3 hours, etc.) within previous 30 days.
• •Subjects who are pregnant (or plan to become pregnant within 3 months of investigational product treatment) or lactating.
• •Subjects who have a significant concomitant illness as judged by principal investigator (PI).
• •Subjects with known human immunodeficiency virus infection or who are immune compromised.
• •Subjects with a known history of alcohol abuse or drug abuse within the 5 years before study treatment administration.
• •Subjects who are current smokers.
• •Subjects unable to return for follow-up visits for clinical evaluation, laboratory studies, or imaging evaluation.
• •Subjects with a history of severe allergic or anaphylactic reactions.
• •Subjects with known allergy or hypersensitivity to any component of the formulation or hypersensitivity to any component of the formulation (normal saline and human serum albumin).
• •Subjects who have participated in another clinical study of new investigational therapies or have received an investigational therapy within the 12 weeks before study drug administration.
• •Subjects with known Alpha-1 antitrypsin deficiency.
• •Subjects with current active infection including pulmonary infection, systemic infection or severe local infections.
• •Subjects with exacerbation of COPD within the 12 weeks before study treatment administration.
• •Subjects who have the following conditions in laboratory tests at screening;
• •1. \>2 × upper limit of normal (ULN) for alanine aminotransferase (ALT) or aspartate aminotransferase (AST); or
• •2. \>2 × ULN for serum creatinine.